MetaVia Inc. is trading at $1.84 (6.1% down) as initial gains tied to its obesity and metabolic pipeline update faded during regular trading.
- Investors were anticipating new data from a company presentation on novel obesity and metabolic therapies at an Emerging Growth Conference.
- With no major surprises or new data disclosed, traders appear to be unwinding short-term speculative positions following recent sharp volatility.